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Placental dysfunction leads to foetal damage, which jeopardises the exchange between the maternal and
foetal systems. We evaluated the effects of tumour growth on the activity of antioxidant enzymes and
oxidative stress in placental tissue and cell culture from tumour-bearing pregnant rats compared to non-
tumour-bearing pregnant rats that were ascitic ﬂuid injected. Ascitic ﬂuid is obtained from Walker
tumour-bearing rats and contains a cytokine called Walker factor (WF), which is a molecule similar to
proteolysis-inducing factor (PIF), and induces changes in protein metabolism and oxidative stress.
Pregnant Wistar rats were distributed into control (C), tumour-bearing (W) and ascitic ﬂuid injected (A)
groups and were sacriﬁced on days 16, 19 and 21 of pregnancy to analyse the proﬁle of enzyme activities
(glutathione-S-transferase (GST), catalase (CAT), alkaline phosphatase (AP)) and malondialdehyde (MDA)
content in placental tissue. Meanwhile, placenta samples from all groups were obtained on day 21, placed
in primary culture and treated with WF for 72 h. The presence of tumour or ascitic ﬂuid reduced the
protein content of the placental tissue. On day 16 there was a signiﬁcant reduction in AP activity in W
rats, and on day 19, CAT activity and MDA content signiﬁcantly increased. These results indicate that the
presence of cancer decreased antioxidant enzyme capacity in the placenta, increasing the amount of
oxidation in these cells, which may contribute to irreversible placental damage and compromisefoetal
development. WF treatment induces similar changes in placental cells in primary culture, resulting in
less cell viability and increased oxidative stress. These results indicate that WF, provided by the tumour
or inoculation of ascitic ﬂuid, has negative effects on placental homeostasis, which impairs foetal health.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The placenta is a remarkable organ that enables the exchange of
nutrients and metabolic products between the mother and fetus to
ensure proper foetal development [1]. The placenta contains highly
specialised trophoblast cells that form a barrier between the
maternal uterus and the fetus [1e3]. The growth of this organ is
maintained by the maternal blood supply [4], which provides an
adequate balance of nutrients, growth factors and hormones [5].
Alterations in this balance may result in several disorders charac-
terised by increased oxidative stress in the placenta, such as pre-
eclampsia, which is believed to result from maternal endothelial
dysfunction [6,7].
Some pathological conditions (e.g., diabetes and pre-eclampsia)
or conditions of malnourishment (e.g., protein-calorie malnutrition
and adolescent pregnancy) are correlated with a reduced placental
adaptation to oxidative stress [8e11]. An imbalance between theþ55 21 1935216784.
es-Marcondes).
Elsevier OA license.production of reactive oxygen species (ROS) and the antioxidants
capacity to inhibit oxidative damage could result in damage to
macromolecules [12,13], which can result in the impairment of
placental cell function and nutrient exchange between the mother
and fetus. Antioxidant enzymes include Mn or Cu superoxide dis-
mutase (SOD), catalase, glutathione peroxidase (GPx) and thio-
redoxin peroxidase (TPx) [14], which can counteract the deleterious
actions of ROS and protect against cell damage [15].
Cancer during pregnancy is uncommon but does occur with an
average frequency of 1 in 1000 births. Therefore, in the case of
cancer during pregnancy, the course of treatment must take into
account the unborn infant. Themechanisms that insure the survival
of fetus during pregnancy presumably also favour the progression
of neoplasia [16]. In previous work, we showed that pregnant rats
withWalker 256 tumours had impaired foetal growth that resulted
in signiﬁcant changes in placental weight and protein content. In
addition, increased haemorrhage and oedemawere associatedwith
high foetal resorption [17].
Tumours can increase the amount of pro-oxidant compounds
and reduce the activity of antioxidant enzymes in extratumoural
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Fig. 1. Placental cells in primary culture images (A) from control, tumour-bearing dams
or Walker factor treated, assessed at 72h treatment. Cell viability (B) of placenta cells in
culture from control and tumour-bearing dams treated with Walker factor was
assessed at 24, 48 and 72 h following treatment. Walker factor western blot image (C).
Arrows show dead cells ﬂoating in a different plane of view. Legend: C e control; W e
tumour-bearing dams; WF1 - treatment with 1 mg/mL of Walker factor protein; WF3 e
treatment with 3 mg/mL of Walker factor protein; WF5 - treatment with 5 mg/mL of
Walker factor protein; WF10 - treatment with 10 mg/mL of Walker factor protein
(n ¼ 8/group) Western blot image M correspond to marker and WF sample of puriﬁed
ascitic ﬂuid. Magniﬁcation 50x. *P < 0.05, statistical difference of W and WF1
compared to C; #P < 0.05, WF3, WF5 and WF10 compared to C.
M.T. Toledo et al. / Placenta 32 (2011) 859e864860tissues [18]. Because tumours can markedly alter the oxidative
metabolism of distant tumour-free tissues and host organs in
general, we examined the activity of key antioxidant enzymes and
the level of oxidative stress in both placental tissue and placental
cells in culture that were obtained from tumour-bearing and and
non-tumour-bearing, pregnant rats.
2. Materials and methods
2.1. Animal
Adult (90-day-old), female Wistar rats (n ¼ 92), obtained from the State
University of Campinas (UNICAMP), were maintained in the Nutrition and Cancer
Research Laboratory at 22 2 C on a 12 h light/dark cycle with free access to a semi-
synthetic control diet (AIN-93) [19] and water. All of the experimental protocols
were approved by the Institutional Committee for Ethics in Animal Experimentation
(CEEA/IB/UNICAMP, number # 034-5) and followed the general UKCCR guidelines
for animal welfare.
Pregnant rats were conﬁrmed by analysing vaginal smears after mating for 12 h.
The pregnant rats were distributed into three groups: control (C), tumour-bearing
(W), and ascitic ﬂuid injected (A). In order to evaluate the response proﬁle of the
placenta to oxidative stress, rats were sacriﬁced on days 16, 19 and 21 after mating.
2.2. Tumour implantation and collection of ascitic ﬂuid and walker factor
A suspension ofWalker 256 carcinoma cells (approximately 2.5105 viable cells
in 0.5 mL) was subcutaneously injected on the 2nd day of pregnancy; control rats
were injected with 0.5 mL of 0.9% NaCl (w/v) solution [20].
Ascitic ﬂuid was obtained from the peritoneal cavity of Walker 256 tumour-
bearing rats and centrifuged at 500  g for 10 min to remove all neoplastic cells.
The ascitic ﬂuid (2 mL) was administered daily by i.p. injection beginning on the 9th
day of gestation. Repeated injections of NaCl, used as a control, and administrated
similarly to ascitic ﬂuid, had no effect on placental development and growth [20]. All
experiments were conducted on days 16, 19 and 21 after tumour transplantation or
ascitic ﬂuid treatment.
Walker factor (WF), a proteolysis-inducing factor (PIF)-like molecule, was
puriﬁed from ascitic ﬂuid of Walker tumour-bearing animals. Ascitic ﬂuid was
centrifuged and processed by precipitating the large proteins and the 24 KDa WF
proteinwas puriﬁed and concentrated by ﬁltering in aMILLIPOREmembrane system
5 KDa [21]. The presence of WF was conﬁrmed by western blot analysis according to
Yano et al. [21].
2.3. Placental cell culture
Four separate placental tissues were collected from each rat in the C and W
groups on the 21st day of pregnancy (minimum of 5 dams per group). After
removing the residual foetal and maternal tissues, small pieces of placental tissue
were dissected and washed twice in sterile PBS with 100 IU/mL penicillin, 100 mg/mL
streptomycin and 10% Fungisone. After trypsin digestion (0.25%), 2  106 viable cells
were cultured in DMEM culture medium containing 10% FBS and the above
supplements in a humidiﬁed atmosphere of 5% CO2 at 37 C. All experiments were
initiated using cells grown to 90e100% conﬂuence after the 10th day of culture.
For all assays, the conﬂuent placental cells were distributed into three experi-
mental groups: control (C), tumour-bearing (W, placental tissue from pregnant,
tumour-bearing rats) and control treated with 1.0, 3.0, 5.0 or 10.0 mg/mLWF protein
in DMEM (WF, placental tissue from pregnant, control rats). After 24, 48 or 72 h of
treatment with or withoutWF, the cells were compared under a microscope (50x) to
assess the cell viability using trypan blue.
After 72 h, cells with and without treatment were washed in cold PBS to arrest
cellular metabolism and were then collected in homogenisation buffer (HB, 20 mM
Tris, 1 mM DTT, 2 mM ATP and 5 mM MgCl2, pH 7.2). The homogenates were
centrifuged for 10 min at 500x g, and the supernatant was collected for biochemical
analysis (protein concentration; GST, catalase and alkaline phosphatase activities;
lipid peroxidation and DNA fragmentation), as described below.
2.4. Analytical methods
2.4.1. Biochemical analysis
Tissue samples from the placenta were weighed, homogenised in homogeni-
sation buffer and centrifuged for 30 min at 4000 rpm; the supernatant was collected
for biochemical analysis. The protein concentrations of tissue and cell homogenates
were determined by the Bradford method [22] using bovine serum albumin (BSA) as
a standard. All samples were assayed in triplicate using appropriate dilutions of the
placental extracts.
Aliquots of supernatants of the homogenate (tissue or cells) were assayed for
glutathione-S-transferase (GST) following the conjugation of 1-chloro-2,4-
dinitrobenzene (CDNB) with glutathione. The activity of GST was expressed innmol/min/mg protein [23]. Catalase activity was measured as described by Cohen
et al. [24] and the results were expressed in nmol/min/mg protein. Alkaline phos-
phatase activity was measured using 37 mM 4-nitrophenyl disodium phosphate (p-
NPP) and expressed in nmol/min/mg protein [25]. The malondyaldehyde (MDA)
content was determined using n-methyl-2-phenylindole (MPO) as the substrate and
expressed in nmol/mg protein [26]. To determine the DNA content of the placenta,
the placentawas incubated with 0.5 N sodium hydroxide for 1 h and absorbancewas
measured at 280 and 290 nm. To assess DNA fragmentation, the DNA was isolated
from cultured placental cells and separated into fragmented and integral subunits
using a Trizol/Triton-X method. The amount of DNA from both samples was deter-
mined using SYBR-Green and expressed in ng/mL. Data are expressed as frag-
mented/total DNA [27].
2.5. Statistical analysis
The results were expressed as the mean  SEM. One-way ANOVA [28] followed
by Bonferroni’s test was used to compare the different experimental groups. A value
of p < 0.05 indicates signiﬁcance.
3. Results
3.1. Morphological parameters e cell culture
The cell viability curve (Fig. 1) shows that placental cells from
control (C) andWalker tumour (W) culturesmaintained conﬂuence
after 72 h. However, 21% of the cells in the W group were dead
compared to the C group (Fig. 1). Cell death was observed in
placental cells 48 h after treatment with 1 mg/mL Walker factor
M.T. Toledo et al. / Placenta 32 (2011) 859e864 861(WF1) and increased by 19% 72 h after treatment. Treatment with 3,
5 or 10 mg/mL of WF reduces the number of viable cells by 50, 74
and 84%, respectively (Fig. 1).
3.2. Placental tissue analysis
Protein Content: The protein content in placenta tissue decreased
64.4% and 25.4%, in the tumour-bearing groups (W16 and W19,
respectively) and 67.6% and 52.4% in the ascitic ﬂuid groups (A16
and A19, respectively) (Fig. 2A). On day 21, there was a 28.2%
reduction in the protein content of the placenta in the ascitic group
(A21), when compared to C21 (Fig. 2A).
Alkaline Phosphatase: On day 16, alkaline phosphatase activity
decreased by 51.3% in the tumour-bearing group (W16). Although
not statistically signiﬁcant, due to high variability among samples,
mean alkaline phosphatase activity tended to average 24% lower in
the tumour-bearing group at day 19 and by 41% and 29% in the
ascitic groups at day 16 and 19, respectively, when compared to the
control groups (C16 and C19) (Fig. 2B).
Glutathione-S-Transferase (GST) and Catalase (CAT): GST activity
in placental tissue was similar in both control and tumour-bearing
rats (Fig. 2C). There was a signiﬁcant reduction (up to 50%) in the
GST activity in the placenta from the ascitic ﬂuid group (A16)
(Fig. 2C). The CAT activity was increased by 3.6 fold in tumour-
bearing dams (W19) and was reduced in the ascitic ﬂuid group
(A16) by44% compared with the C16 group (Fig. 2D).C16 W16 A16 C19 W19 A19 C21 W21 A21
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Fig. 2. Protein content (A) alkaline phosphatase activity (B) glutathione-S-transferase activit
dams sacriﬁced on days 16, 19 or 21 of pregnancy. Legend: C- control, W- tumour-bearing
animals is 10 rats/group for each day of sacriﬁce. *p < 0.05, compared to the correspondinPlacental Malondialdehyde content (MDA): The MDA levels in the
placenta tissue increased approximately 71% and 125.9% in tumour-
bearing pregnant rats after 16 and 19 days of pregnancy (W16 and
W19, respectively) (Fig. 2E).
DNA Content: There was no difference in the placental DNA
content among all groups after 16 days of pregnancy. However, the
presence of tumour decreased the DNA content after 21 days of
pregnancy (Fig. 2F).
3.3. Placental cell culture analysis
Protein content: The protein content was similar in all placental
cell cultures independent of the treatment (Fig. 3A).
Alkaline phosphatase: The alkaline phosphatase activity
increased in the placental cells obtained from tumour-bearing rats
(W). Walker factor treatment, regardless of concentration, did not
alter the alkaline phosphatase activity (Fig. 2B).
Glutathione-S-transferase and Catalase: There was no statistical
difference in the GST activity of placental cells treated with WF
(Fig. 3C). In contrast, the CAT activity was reduced in the WF10
treatment group (62.7% lower) (Fig. 3D) compared with the other
treatments.
MDA content: There was no statistical difference in the MDA
levels of cultured cells treated with Walker factor (WF) (Fig. 3E).
Fragmented DNA: The placental cell cultures from the Walker
tumour group (W) and the group treated with 5 mg/mL of WalkerC16 W16 A16 C19 W19 A19 C21 W21 A21
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Fig. 3. Protein content (A), alkaline phosphatase activity (B), glutathione-S-transferase activity (C), catalase activity (D), MDA content (E) and fragmented DNA (F) in cultured
placental cells from tumour-bearing or non-tumour-bearing dams. C- control, W- tumour-bearing, WF- Treated with Walker factor at 1 mg/mL, 3 mg/mL, 5 mg/mL or 10 mg/mL. The
results are the mean þ SEM of 5 rats/group. *p < 0.05, compared to control groups.
M.T. Toledo et al. / Placenta 32 (2011) 859e864862factor (WF5) showed a higher percentage of fragmented DNA
(Fig. 3F).
4. Discussion
Few studies have examined the effects of cancer on pregnancy.
Although uncommon, there are many tumours, such as breast
cancer, one of the most common cancers that can occur concomi-
tantly with pregnancy [29e31]. Tumour growth can be detrimental
to the mother, fetus and maternal-foetal unit. The rapid growth of
Walker 256 tumours during pregnancy adversely affects foetal
development [32] and placental homeostasis, as previously
described [17,33e35]. Because the growth and metabolic charac-
teristics of the fetus are very similar to those of rapidly growing
tumours, there is competition for the nutritional supply between
the fetus and the tumour in a pregnant mother with cancer. In
addition, factors produced by the tumour or by the host in trying to
ﬁght the tumour, such as cytokines and humoural factors, can
jeopardise the foetal development. Our previous studies have
demonstrated that tumour-produced factors have a greater effect
on foetal development than inadequate nutrition. For example,
ascitic ﬂuid injected into pregnant, non-tumour-bearing rats results
in a similar level of a foetal resorptions and deaths compared to
tumour-bearing pregnant rats, which is not observed in rats with
low foetal weight [17,20,36]. The fetuses of malnourished, pregnant
rats have a lower weight rather than undergoing foetal resorptionand death [37,38]. The present work demonstrates an increase in
oxidative stress in both placental tissue and placental cells in
culture in response to the tumour. These effects can be seen
throughout the growth of the tumour and also by theWalker factor
resulting in changes in antioxidant enzyme activity, oxidative stress
biomarkers (MDA content) and DNA fragmentation.
As shown in our previous studies, tumour growth signiﬁcantly
reduced foetal and placental weight indicating impairment in foetal
development [33,36]. In association with advanced gestational age,
Walker tumour leads to a high number of foetal resorption sites
[20,33]. In addition, haemorrhage and oedemawere seen inplacental
tissue from tumour-bearing and ascitic ﬂuid injected rats, suggesting
that tumour-produced factors are responsible for placental damage
[17,20]. In the present study, the results suggest that placental tissues
or placental cells in culture obtained from tumour inoculated and
ascitic ﬂuid injected rats were negatively affected by tumour factors
throughout the duration of the pregnancy.
The normal development of a placenta is essential for the
growth of a healthy fetus, and placenta function is critical at all
stages of pregnancy. Protein malnutrition and a calorie deﬁcit can
restrict intrauterine growth [37,39]. On the other hand, food
restriction during pregnancy does not compromise placental
growth [40]. Maternal malnutrition resulting from cancer does not
interfere with normal placental growth. However, as seen here,
direct and/or indirect tumour effects can lead to reduced weight
and protein content of the placenta [20], possibly a consequence of
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synthesis. Studies have reported that the maximum rate of protein
synthesis in rat placenta is achieved on day 19 of pregnancy, as we
have conﬁrmed in our study. Placental protein synthesis can also be
regulated through the Akt/mTOR pathway [34]. Investigations by
Yang et al. [41] demonstrated that genetic knockout of Akt1 in the
mouse resulted in placental and foetal growth retardation. Yung
et al. [35] demonstrated that a decrease in 4E-BP1 phosphorylation
in human placentas derived from fetuses with intrauterine growth
restriction (IUGR) could result in a reduction in placental protein
synthesis. We have previously demonstrated that Walker tumour
andWalker factor (PIF-like) can changemuscle protein synthesis by
reducing eukaryotic initiation factors (eiF4E, eiF4G and p70S6ki-
nase). Presumably this can also occur in placental cells [21].
Reduction in placental protein content appears to be indicative of
tissue damage mediated by tumour factors [42,43]. For example,
Walker Factor treatment damaged placenta tissue and cultured cells,
resulting in reduced cell viability and increased DNA fragmentation.
We have found that tumour growth damages placental tissue by
altering the levels of apoptotic precursors [36]. There is some
evidence for the occurrence of distinct apoptotic pathways in the
placenta of tumour-bearing and ascitic ﬂuid injected rats. Activated
caspase-3 cleaves PARP, one of many caspase substrates, to prevent
this enzyme from repairing damaged DNA, which results in the
initiation of apoptosis. In the present study, we have shown that
placental tissue or placental cells in culture are affected by the
tumour during the course of pregnancy resulting in decreased DNA
content or increased DNA fragmentation.
The formation of ROS during apoptosis could activate other
apoptotic pathways. Various studies have shown an increase in
apoptosis following B19 infection of villous trophoblast cells [44],
an elevation in caspase-3 activity and cytochrome c release in
chorionic villi after exposure to ultrasound [36,45] and higher rates
of apoptosis in placentas from pregnancies complicated with
intrauterine growth restriction [46]. Since trophoblast cells are
responsible for maintaining normal placenta function, the uncon-
trolled death of these cells could have a negative impact on foetal
development. As our viable cell assays conﬁrm, WF treatment
which mimics tumour derived factors, decreases placental cell
viability suggesting a possible direct link between tumour factors
and damage to the placenta.
An imbalance between lipid peroxides and the antioxidant
system may result in placental dysfunction and subsequent inade-
quate nutrient transfer to the fetus. The production of lipid perox-
ides and free radicals by the placenta affects its integrity leading to
placental damage as seen in pre-eclampsia [47] or pregnancy
complications. The elevated level of MDA in pregnant, tumour-
bearing rats by day 19 of pregnancy (W19) could be an indicator
of lipid peroxidation inplacental tissue. In contrast, catalase enzyme
activity in this same group is increased, perhaps due to the ability of
this antioxidant enzyme to eliminate free radical. The presence of
antioxidant enzymes in the placenta increases with normal gesta-
tional progression to protect the own cell activities and also the
fetus against oxidative damage [48,49]. In contrast, cancer causes
oxidative stress, which results in an increased production of free
radicals and a decreased activity of antioxidant enzymes. To conﬁrm
this, Sinha et al. [15] demonstrated an increase in blood levels of
MDA and a reduction in catalase and SOD levels in breast cancer
patients. In the present study, the antioxidant enzyme system in the
tumour-bearing groups was not effective at neutralising the
oxidants because the activity of catalase was increased in tumour-
bearing groups and GST activity was similar to control groups.
Other factors released by the tumour, such as TNF-a, have been
implicated in placenta and foetal weight loss and a decrease in
placental protein content in pregnant rats [17,20,33]. In many celltypes, including human trophoblasts, oxidative stress serves as
a signal to directly or indirectly activate apoptosis. Although
apoptosis occurs as part of the normal cell turnover in the placenta,
an excessive amount of apoptosis and oxidative stress may
compromise the functions of the trophoblast and could be a primary
pathological event or a contributing factor in complications expe-
rienced during pregnancy.
In this experimental model, we observed the direct and indirect
effects of Walker Factor (PIF-like) treatment on placental cells.
Since Walker Factor has immunological and molecular weight
characteristics identical to PIF, it also acts by changing host protein
turnover [21] altering cell activity. The cultured cells from tumour-
bearing, pregnant rats (W) showed an increase in alkaline phos-
phatase activity, suggesting alterations in cellular activity [36]. The
increase in alkaline phosphatase activity may inﬂuence apoptosis
in these cells. Cells cultured from tumour-bearing rats (W) may be
correlated with the W21 group (in vivo experiment) that tends to
have enhanced alkaline phosphatase activity. We observed
a correlation between in vivo and in vitro antioxidant enzyme
activities (Cat and GST) and lipid peroxidation (MDA) whereby the
C and W groups demonstrated similar results observed in the C21
and W21 groups. These data indicate that Walker Factor may
exacerbate placental dysfunction, which is characterised by
changes in placenta architecture and loss of cell adhesion. Treat-
ment of placental cells in culture with WF resulted in a dose- and
time-dependent decrease in the number of cells, as well as modi-
ﬁed cell morphology, which is important in placenta physiology
[50]. Walker factor treatment may interfere in reductioneoxidation
reactions resulting in an increase in oxidative stress. While cellular
mechanisms (slight increase in GST and CAT activities) attempt to
neutralise lipid peroxidation, these mechanisms may be insufﬁ-
cient to compensate for the increased oxidative stress produced by
the tumour. This results in Walker factor (PIF-like) interfering in
placental cellular activity, reduced cell viability by altering enzyme
activities and caused DNA fragmentation. Many malignancies could
alter the normal course of pregnancy and impair the maternal/
foetal unit by restricting foetal health and placenta homeostasis.
Further studies are now underway in our laboratory to determine
the cell signalling events in placenta that occur during pregnancy as
a result of tumour development.Acknowledgement
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